Like ClinicalAnalytics(R)

closed 11/17/2008 via PR Newswire

Clinsys Clinical Research, Inc., purchased ClinicalAnalytics(R) from TrialStat Corporation

synopsis: Jubilant Organosys Ltd. announced that its subsidiary Clinsys Clinical Research, Inc.(R), New Jersey, a global contract research organization (CRO), has acquired TrialStat ClinicalAnalytics(R) from TrialStat(R) for a purchase consideration of CAD 750,000.
buyer parent: Jubilant Organosys Ltd.
buyer: Clinsys Clinical Research, Inc.
Clinsys Clinical Research, Inc.®, a Jubilant Organosys company, is a therapeutically focused clinical research organization. We provide pharmaceutical, biotechnology and medical device companies with a broad range of clinical research services. "
seller: TrialStat Corporation
TrialStat is a technology and services company providing powerful, cost-effective turn-key data capture and management tools for researchers and investigators in health care. TrialStat provides industrial strength data management software solutions to the clinical research community.
price ($mm)
$0.62
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
closed 12/1/2020 via PR Newswire

Signant Health, acquired VirTrial

synopsis: Signant Health has acquired VirTrial, a provider of software solutions for remote site startup and decentralized clinical trial conduct. With the acquisition, Signant Health expands its software stack to further digitally enhance trial sites and offer sponsors superior evidence generation across traditional, decentralized, and hybrid trial models.
buyer parent: Genstar Capital LLC
buyer: Signant Health
Signant Health is the evidence generation company. Signant is focused on leveraging software, deep therapeutic and scientific knowledge, and operational expertise to consistently generate quality evidence for clinical studies across traditional, virtual, and hybrid trial models. "
target parent: Kinderhook Industries
target: VirTrial
VirTrial's virtual care platform enables pharmaceutical companies and Contract Research Organizations to empower their preferred clinical research sites to perform virtual visits through a combination of secure video, audio, chat, and messaging, which can be used on any device.
price ($mm)
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
closed 5/5/2014 via BusinessWire

DrugDev, acquired TrialNetworks

synopsis: DrugDev, the industry’s largest global network of active clinical trial doctors, announced its acquisition of TrialNetworks. The award-winning TrialNetworks platform is a Clinical Trial Optimization System that transforms the quality, efficiency and ongoing management of clinical operations.
buyer: DrugDev
DrugDev streamlines engagement among sponsors, CROs and doctors to advance the common goal of doing more trials. Through the creation of global, standardized processes DrugDev is consistently and efficiently transforming the way drug developers identify, engage and pay investigators. "
target parent: Epernicus
target: TrialNetworks
TrialNetworks platform is a unified, cloud-based suite of collaborative trial management apps and site-facing tools designed to improve processes, ensure transparency and streamline timelines for key aspects of clinical operations.
price ($mm)
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
closed 6/26/2013 via Yahoo, Inc.

Cenduit, acquired Patient Reminders Ltd

synopsis: Cenduit has acquired Patient Reminders, a unique service that allows clients/sponsors to reach patients directly with personalized messages and reminders about crucial aspects of their study – thus increasing subject compliance and retention in clinical trials – without purchasing special devices.
buyer: Cenduit
Cenduit provides sponsors with the clinical operations and supply chain expertise, interactive response technology (IRT) and system control they need to ensure Every Patient, On Time, Every Time. "
target: Patient Reminders Ltd
Patient Reminders Ltd provides a software-as-a-service (Saas) patient reminders platform, which can be used by anyone to build elegant patient, caregiver and site alerts using SMS, eMail, iCal and or IVR.
price ($mm)
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
closed 2/3/2021 via BusinessWire

Netsmart Technologies, Inc., acquired Geriatric Practice Management Corp

synopsis: Netsmart, a healthcare software company, has acquired Geriatric Practice Management Corp (GPM Corp), a SaaS technology and services company serving the long-term/post-acute care (LTPAC) community. GPM Corp provides a cloud-based, mobile EHR platform built for LTPAC practitioners. They also offer a clinical documentation and messaging platform.
buyer parent: GI Partners
buyer: Netsmart Technologies, Inc. (:$59.05)
Netsmart designs, builds and delivers electronic health records (EHRs), health information exchanges (HIEs), population health management, analytics, and telehealth solutions and services that are powerful, intuitive, and easy-to-use. "
target: Geriatric Practice Management Corp
Geriatric Practice Management Corp (GPM Corp) is a SaaS technology and services company serving the long-term/post-acute care (LTPAC) community. GPM Corp provides a cloud-based, mobile EHR platform built for LTPAC practitioners. They also offer a clinical documentation and messaging platform.
price ($mm)
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
closed 6/4/2008 via BusinessWire

MedData, acquired ManagedCare.com

synopsis: MedData, a division of AGDATA, LP, has acquired healthcare analytics firm ManagedCare.com. The move strengthens MedData’s position as a leading provider of real-time and other healthcare EDI and managed care services integrated with data analytics and business intelligence tools.
buyer parent: AGData
buyer: MedData
MedData is the healthcare division of AGDATA, L.P. MedData was formed to apply and use state-of-the-art database and real-time transaction processing technology for the healthcare industry. "
target: ManagedCare.com
Since 1995, ManagedCare.com has provided development, management and operations consulting to a variety of provider and other organizations. ManagedCare.com provides a full continuum of advisory services to IPAs, PHOs and other managed care organizations.
price ($mm)
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
closed 4/4/2018 via BusinessWire

SCI Solutions, Inc., acquired DatStat, Inc.

synopsis: SCI Solutions, a leading patient access and care coordination software company, announced it has acquired DatStat, a leading provider of patient engagement and digital health tools.
buyer: SCI Solutions, Inc.
SCI Solutions empowers provider networks and health systems to capture the economic value of their community relationships by making it easier to acquire and keep patients, coordinate access to appropriate care, and grow market share. "
target: DatStat, Inc.
DatStat is leading provider of patient engagement and digital health tools. DatStat’s consumer-ready tools function on any device, so patients can securely message providers, confirm adherence to care plans and receive important reminders for appointment follow-up.
price ($mm)
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
closed 8/26/2013 via PR Web

Orange Health Solutions, acquired ExtendMD, LLC

synopsis: Orange Health announced it completed its acquisition of all ExtendMD software assets . The software was developed, in partnership with several of the best medical academic institutions in the world, as an easy way for patients with chronic conditions to communicate their ‘at home’ readings directly to their healthcare team.
buyer: Orange Health Solutions
Orange Health Solutions provides innovative solutions to its healthcare partners, allowing them to deliver higher quality coordinated care, improved population health management, increased efficiency and positively impact financial success. "
target: ExtendMD, LLC
ExtendMD uses simple, everyday technologies to increase the communication between patients and doctors dramatically reducing overall healthcare costs and saving lives. It is an easy way for patients with chronic conditions to communicate their ‘at home’ readings directly to their healthcare team.
price ($mm)
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
closed 12/6/2010 via BusinessWire

NaviNet, Inc., acquired Prematics, Inc.

synopsis: NaviNet, America’s largest real-time healthcare communications network, announced that it has acquired Prematics, Inc., a leading provider of mobile care management solutions, expanding NaviNet’s clinical product suite for unified patient information management (UPIM).
buyer: NaviNet, Inc.
NaviNet, America’s largest real-time healthcare communications network, securely links leading health plans, industry partners and the government to hundreds of thousands of physicians, clinicians and other healthcare professionals. "
target parent: Health Evolution Partners LLc
target: Prematics, Inc.
Prematics, a market leader in electronic prescribing, has used that platform as an on-ramp to pioneer the new generation of care communication that not only reduces chronic care management costs, but also improves quality, minimizes redundant therapies, and promotes preventative care.
price ($mm)
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
closed 3/1/2017 via Company Press Release

OmniSYS, LLC, acquired Voice-Tech, Inc.

synopsis: OmniSYS, LLC announced that it has acquired voiceTech—a leading technology provider to the pharmacy industry. voiceTech's Fusion-Rx provides a feature-rich patient communication and adherence platform that fully integrates advanced inbound IVR and Star-adherence outbound messaging as part of patient, pharmacy, and prescriber services.
buyer parent: NexPhase Capital
buyer: OmniSYS, LLC
OmniSYS is a healthcare IT company that helps pharmacies drive profitable growth. With over two decades of domain expertise, OmniSYS is the market leader in medical, immunization and DME claim billing, patient communication and adherence, as well as consumer-engagement workflow. "
target: Voice-Tech, Inc.
voiceTech develops Fusion-Rx, a next generation patient communication & adherence platform. It provides pharmacies with advanced inbound IVR, Star adherence outbound messaging, data security safeguards, VoIP connectivity or traditional phone line integration, and much more.
price ($mm)
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
closed 4/24/2019 via Company Press Release

Cardinal Health, Inc., acquired mscripts, LLC

synopsis: Cardinal Health, a global, integrated healthcare services and products company, providing customized solutions, announced the acquisition of mscripts®, a company that delivers patient adherence and engagement solutions through an innovative, easy-to-use mobile and web-based health management platform. 
buyer: Cardinal Health, Inc. (CAH:$141,935.00)
Cardinal Health, Inc. is a global, integrated healthcare services and products company, providing customized solutions for hospitals, healthcare systems, pharmacies, ambulatory surgery centers, clinical laboratories and physician offices worldwide. "
target: mscripts, LLC
mscripts delivers patient adherence and engagement solutions through their innovative, easy-to-use mobile and web health management platform. They serve millions of patients spanning national, regional and specialty pharmacies along with hospital out-patient systems.
price ($mm)
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
announced 3/25/2019 via Company Press Release

CMIC Healthcare Co., Ltd., will acquire harmo

synopsis: Japan's CMIC Healthcare, whose main business is a patient support program that supports medication adherence and continuing hospital visits, will acquire Japanese electronic medicine notebook business "harmo" from Sony Corporation. "harmo" allows users to share their prescription information simply by tapping the harmo card against a reader.
buyer parent: CMIC Co., Ltd.
buyer: CMIC Healthcare Co., Ltd.
Japan's CMIC Healthcare provides services and solutions to patients, and is mainly operated by nurses, pharmacists, clinical laboratory technicians, and registered dietitians. Their main business is a patient support program that supports medication adherence and continuing hospital visits. "
target parent: Sony Corporation
target: harmo
Harmo is an electronic prescription record service that is the largest Personal Health Record platform in Japan. It is based on innovative technologies that enable feedback to individuals while maintaining anonymity by physically separating and managing information that identifies individuals.
price ($mm)
$0.01
rev ($mm)
$1
EBITDA ($mm)
EV / rev
0.0x
EV / EBITDA
closed 10/17/2018 via BNC Analysis

OptimizeRx, acquired CareSpeak Communications

synopsis: OptimizeRx, a leading provider of digital health messaging for the pharmaceutical industry, has acquired CareSpeak Communications, a leader in interactive health messaging for improved medication adherence and care coordination.
buyer: OptimizeRx (OPRX:$24.21)
OptimizeRx is one of the nation’s leading providers of digital health messaging via electronic health records, providing a direct channel for pharma companies to communicate with healthcare providers. "
target: CareSpeak Communications
CareSpeak Communications’ HIPAA compliant and HITRUST certified Automated Patient Engagement Platform helps patients be more compliant with their medical therapy and supports them throughout their healthcare journey via interactive messaging, and care coordination interventions.
price ($mm)
$6.00
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
closed 6/27/2018 via Company Press Release

Aptus Health, acquired Engaged Media LLC

synopsis: Aptus Health—a leader in multichannel engagement solutions—is pleased to announce its acquisition of the Atlanta-based company Engaged Media. Engaged Media provides a mobile-first messaging platform that enables life sciences companies to communicate and engage with patients based on real-time pharmacy claims data.
buyer parent: Merck & Co., Inc.
buyer: Aptus Health
Aptus Health offers health and life sciences companies a truly connected approach to engaging healthcare professionals, consumers and other stakeholders through an array of high-value digital information channels and services. "
target: Engaged Media LLC
Atlanta-based company EngagedMedia provides a mobile-first messaging platform that enables life sciences companies to communicate and engage with patients based on real-time pharmacy claims data.
price ($mm)
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
closed 5/6/2013 via Company Press Release

PatientOrderSets, acquired fliiSolutions Inc.

synopsis: PatientOrderSets announced the acquisition of a patient self-management technology, fliiSolutions Inc. It is used to track patients’ compliance with care plans, including medication schedules, rehabilitation programs, vital signs, and other relevant metrics, allowing patients in the community to be effectively supervised by a clinician remotely.
buyer: PatientOrderSets (TSXV:THNK:$15.41)
PatientOrderSets is a leading provider of evidence-based order sets and checklists used by doctors, nurses and pharmacists to dramatically improve patient safety, save clinicians' time, and significantly reduce costs. "
target: fliiSolutions Inc.
fliiSolutions was founded in 2012 to help patients better connect with their healthcare providers. The company’s solutions include fliiTherapy, which enables healthcare providers to connect with patients by creating and maintaining a 2-way communication link.
price ($mm)
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
announced 4/7/2021 via BusinessWire

Everbridge, will acquire xMatters, inc.

synopsis: Everbridge, a global software company, is to acquire xMatters, a service reliability platform that helps DevOps, Site Reliability Engineers (SREs), and operations teams rapidly deliver products at scale by automating workflows and ensuring infrastructure and applications are always working.
buyer: Everbridge (EVBG:$200.88)
Everbridge, Inc. is a global software company that provides enterprise software applications that automate and accelerate organizations’ operational response to critical events in order to keep people safe and businesses running. "
target: xMatters, inc.
xMatters is a service reliability platform that helps DevOps, Site Reliability Engineers (SREs), and operations teams rapidly deliver products at scale by automating workflows and ensuring infrastructure and applications are always working.
price ($mm)
$240
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
closed 1/26/2016 via PR Newswire

PetalMD, acquired Medago

synopsis: PetalMD, a cloud-based application featuring productivity tools for healthcare professionals, announced the acquisition of Montreal-based Medago, a company that allows doctors and dentists to send their medical prescriptions directly to the patient's pharmacy.
buyer: PetalMD
PetalMD is a cloud-based application featuring productivity tools for healthcare professionals including scheduling, shift transfers, and secure messaging. "
target: Medago
Medago is a Montreal-based healthcare technology company. Medago's mission is to revolutionize the way healthcare professionals communicate by allowing doctors and dentists to send their medical prescriptions directly to the patient's pharmacy.
price ($mm)
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
closed 8/11/2021 via BNC Analysis

Raia Drogasil S.A., acquired CUCO Health

synopsis: Raia Drogasil (RD), the largest pharmacy chain in Brazil, has acquired CUCO Health, a mobile health platform in Brazil. CUCO Health helps patients to follow their care plan when they are alone. The app allows patients to set alarms for when they need to take their medication.
buyer: Raia Drogasil S.A. (BOVESPA:RADL3:$4,215.40)
Raia Drogasil (RD) is the largest pharmacy chain in Brazil. RD operates more than 2,300 stores in 24 Brazilian states. The company aims to build a healthier world and improve the well-being of all people through their brands and businesses. "
target: CUCO Health
CUCO Health is a mobile health platform in Brazil. CUCO Health helps patients to follow their care plan when they are alone. The app allows patients to set alarms for when they need to take their medication. It also sends alarms to caregivers if the patient forgets to take their pills on time.
price ($mm)
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
closed 4/24/2014 via Market Wire

Zynx Health, acquired CareInSync

synopsis: Hearst Health announced its acquisition of CareInSync, a software solutions company providing a real-time, mobile platform to improve patient care by enhancing communications between care providers and patients. CareInSync will become part of Zynx Health, the market leader in providing evidence- and experience-based clinical improvement solutions.
buyer parent: The Hearst Corporation
buyer: Zynx Health
Zynx Health, part of the Hearst Health network, is the pioneer and market leader in evidence- and experience-based clinical improvement solutions that provide the care guidance to enhance quality and decrease variation across an individual's health journey. "
target: CareInSync
CareInSync offers software solutions that improve communication between disparate healthcare providers via a real-time, mobile, collaboration platform.
price ($mm)
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
closed 12/19/2018 via Company Press Release

Change Healthcare Corporation, acquired PokitDok Inc.

synopsis: Change Healthcarehas acquired intellectual property (IP) and other key assets from PokitDok, Inc., a platform-as-a-service company for healthcare. PokitDok’s platform-as-a-service makes it faster and easier for healthcare organizations to bring new applications and services to market.
buyer parent: McKesson Corporation
buyer: Change Healthcare Corporation (CHNG:$1,646.91)
Change Healthcare is inspiring a better healthcare system. Working alongside their customers and partners, they leverage their software and analytics, network solutions, and technology-enabled services to enable better patient care, choice, and outcomes at scale. "
target: PokitDok Inc.
PokitDok’s platform-as-a-service makes it faster and easier for healthcare organizations to bring new applications and services to market. Plug directly into over 700 payers to integrate real-time, member-specific health insurance data at scale.
price ($mm)
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
closed 11/17/2008 via PR Newswire

Clinsys Clinical Research, Inc., purchased ClinicalAnalytics(R) from TrialStat Corporation

synopsis: Jubilant Organosys Ltd. announced that its subsidiary Clinsys Clinical Research, Inc.(R), New Jersey, a global contract research organization (CRO), has acquired TrialStat ClinicalAnalytics(R) from TrialStat(R) for a purchase consideration of CAD 750,000.
buyer parent: Jubilant Organosys Ltd.
buyer: Clinsys Clinical Research, Inc.
Clinsys Clinical Research, Inc.®, a Jubilant Organosys company, is a therapeutically focused clinical research organization. We provide pharmaceutical, biotechnology and medical device companies with a broad range of clinical research services. "
seller: TrialStat Corporation
TrialStat is a technology and services company providing powerful, cost-effective turn-key data capture and management tools for researchers and investigators in health care. TrialStat provides industrial strength data management software solutions to the clinical research community.
price ($mm)
$0.62
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
closed 11/17/2008 via PR Newswire

Clinsys Clinical Research, Inc., purchased ClinicalAnalytics(R) from TrialStat Corporation

synopsis: Jubilant Organosys Ltd. announced that its subsidiary Clinsys Clinical Research, Inc.(R), New Jersey, a global contract research organization (CRO), has acquired TrialStat ClinicalAnalytics(R) from TrialStat(R) for a purchase consideration of CAD 750,000.
buyer parent: Jubilant Organosys Ltd.
buyer: Clinsys Clinical Research, Inc.
Clinsys Clinical Research, Inc.®, a Jubilant Organosys company, is a therapeutically focused clinical research organization. We provide pharmaceutical, biotechnology and medical device companies with a broad range of clinical research services. "
seller: TrialStat Corporation
TrialStat is a technology and services company providing powerful, cost-effective turn-key data capture and management tools for researchers and investigators in health care. TrialStat provides industrial strength data management software solutions to the clinical research community.
price ($mm)
$0.62
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
announced 9/25/2017 via BusinessWire

Konica Minolta, Inc., will acquire Invicro, LLC

synopsis: Konica Minolta, Inc. and Boston-based Invicro LLC announced that they have concluded an agreement whereby Konica Minolta will acquire Invicro, a leading provider of imaging services and software for research and drug development.
buyer: Konica Minolta, Inc. (TSE:4902:$8,793.96)
Konica Minolta, Inc. is a Japanese technology company headquartered in Tokyo. The company manufactures business and industrial imaging products, including copiers, laser printers, multi-functional peripherals (MFPs) and digital print systems for the production printing market. "
target: Invicro, LLC
Invicro is a leading provider of imaging services and software for research and drug development. Headquartered in Boston, Massachusetts, Invicro LLC was founded in 2008 with the mission of improving the role and function of imaging in drug discovery and development across all therapeutic areas.
price ($mm)
rev ($mm)
$106
EBITDA ($mm)
$17
EV / rev
0.0x
EV / EBITDA
0.0x
closed 8/16/2017 via BusinessWire

Evotec BioSystems GmbH, acquired Aptuit, Inc.

synopsis: Evotec announced that it has successfully completed the acquisition of Aptuit, a partner research organisation for integrated outsourced drug discovery and development solutions. This acquisition adds considerable business opportunities to further accelerate Evotec's long-term strategy to be the industry partner of choice for external innovation.
buyer: Evotec BioSystems GmbH (XTRA:EVT:$226.46)
Founded in Hamburg Germany, Evotec BioSystems GmbH is a drug discovery alliance and development partnership company focused on rapidly progressing innovative product approaches with leading pharmaceutical and biotechnology companies, academics, patient advocacy groups and venture capitalists. "
target parent: Welsh, Carson, Anderson & Stowe
target: Aptuit, Inc.
Aptuit, Inc. (formerly Global Pharmaceutical Development, Inc.) is an emerging company focused on streamlining and supporting the drug development process for biotechnology and pharmaceutical innovators.
price ($mm)
$300
rev ($mm)
$93
EBITDA ($mm)
$12
EV / rev
3.2x
EV / EBITDA
25.8x
announced 6/20/2017 via Company Press Release

Pamplona Capital Management LLP, will acquire PAREXEL International Corporation

synopsis: Pamplona Capital Management, LLP has entered into a definitive agreement to acquire all of the outstanding shares of PAREXEL International Corporation, a leading global biopharmaceutical services provider. PAREXEL provides a broad range of expertise-based clinical research, consulting, medical communications, and technology solutions and services.
buyer: Pamplona Capital Management LLP
Pamplona Capital Management is a London, New York, and Boston-based specialist investment manager established in 2005 that provides an alternative investment platform across private equity, fund of hedge funds, and single-manager hedge fund investments. "
target: PAREXEL International Corporation (PRXL:$1,939.36)
PAREXEL International Corporation is a leading global biopharmaceutical services company, providing a broad range of clinical research, consulting, medical communications, and technology solutions and services to the worldwide pharmaceutical, biotechnology and medical device industries.
price ($mm)[EV]
$4,508 [$4,923]
rev ($mm)
$2,097
EBITDA ($mm)
$343
EV / rev
2.4x
EV / EBITDA
14.6x
announced 5/10/2017 via BNC Analysis

inVentiv Health, Inc. will be merged with INC Research, Inc.,

synopsis: INC Research Holdings, Inc., a leading global Phase I-IV Contract Research Organization ("CRO"), and inVentiv Health, Inc., a leading, global CRO and Contract Commercial Organization will merge. INC Research shareholders will own approximately 53 percent and inVentiv shareholders will own approximately 47 percent of the merged entity.
buyer: INC Research, Inc. (SYNH:$4,730.38)
INC Research is a leading global contract research organization ("CRO") providing the full range of Phase I to Phase IV clinical development services for the biopharmaceutical and medical device industries. "
target parent: Thomas H. Lee Partners, L.P.
target: inVentiv Health, Inc.
inVentiv Health is a global professional services organization designed to help the biopharmaceutical industry accelerate the delivery of much-needed therapies to market. Their Clinical Research Organization (CRO) and Contract Commercial Organization (CCO) offer a differentiated suite of services.
price ($mm)[EV]
$2,453 [$4,552]
rev ($mm)
$2,156
EBITDA ($mm)
$306
EV / rev
2.1x
EV / EBITDA
14.9x
closed 10/3/2016 via BusinessWire

Quintiles Transnational Corp. merged with IMS Health Incorporated,

synopsis: Quintiles IMS Holdings, Inc. announced that it has successfully completed its merger of equals transaction between IMS Health Holdings, Inc. and Quintiles Transnational Holdings Inc. The merger creates a leading information and tech-enabled global healthcare service provider, and a full suite of end-to-end clinical and commercial offerings.
buyer: IMS Health Incorporated (NYSE:IQV:$10,412.00)
IMS Health is a leading global information and technology services company providing clients in the healthcare industry with end-to-end solutions to measure and improve their performance. They connect configurable SaaS applications to complex healthcare data in the IMS One™ cloud platform. "
target: Quintiles Transnational Corp. (Q:$4,497.17)
Quintiles is the world’s largest provider of biopharmaceutical development services and commercial outsourcing services. They help customers navigate the increasingly complex healthcare environment to improve efficiency and to deliver better healthcare outcomes.
price ($mm)
$8,750
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
closed 11/6/2009 via BusinessWire

PPD, Inc., acquired Excel PharmaStudies Inc.

synopsis: PPD, Inc. announced it has completed its acquisition of Excel PharmaStudies, Inc., one of the largest contract research organizations in China. The acquisition strengthens PPD’s full range of drug development services in the country and positions it to capitalize on the tremendous growth of the outsourcing market in Asia Pacific.
buyer: PPD, Inc.
PPD is a leading global contract research organization (CRO) providing discovery, development and post-approval services as well as compound partnering programs. PPD's clients and partners include pharmaceutical, biotechnology, medical device, academic and government organizations. "
target: Excel PharmaStudies Inc.
Excel PharmaStudies, Inc. is a full-service provider of clinical research, registration, biometrics, and training and consultation services. Excel is the leading CRO in China and operates 22 offices worldwide, with more than 300 staff members.
price ($mm)
$16
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
closed 7/17/2009 via PR Newswire

Pierrel SpA, purchased US Operations from Encorium Group Inc.

synopsis: Encorium Group, Inc., a full service multinational clinical research organization, announced that is has completed the previously announced sale of the Company's U.S. business to Pierrel Research USA, Inc., a wholly-owned subsidiary of Pierrel SpA, an international contract research organization listed on Milano's Stock Exchange.
buyer: Pierrel SpA (PIELF:$0.00)
Pierrel S.p.A. is a pharmaceutical company specializing in contract research, development and the manufacture of medicines. The Pierrel Group boasts over 50 years of experience in the pharmaceutical sector, and is one of the main Italian manufacturers of local anaesthetics for dental use. "
seller: Encorium Group Inc.
Encorium is a full-service Contract Research Organization providing comprehensive solutions for pharmaceutical, biotechnology, and medical device companies. At Encorium we recognize the challenges that often arise during drug development.
price ($mm)[EV]
$0.08 [$2.58]
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
announced 4/8/2009 via PR Newswire

Next Fuel, Inc., will acquire Clinical Trials of the Americas, Inc.

synopsis: Clinical Trials of America Inc. announced that it has entered into a binding letter of intent to sell shares equal to approximately 75% of its issued and outstanding shares to Next Fuel Inc., a developer of a proprietary "On Demand" Hydrogen Generation System.
buyer: Next Fuel, Inc.
Next Fuel Inc. is a developer of a proprietary "On Demand" Hydrogen Generation System that is used as fuel for Fuel Cells which produce electricity. "
target: Clinical Trials of the Americas, Inc.
Clinical Trials of the Americas, Inc. provides clinical trial investigator services in dedicated sites throughout the Americas. Initially, we intend to introduce our services in Central America.
price ($mm)
$0.29*
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
closed 3/2/2009 via PR Newswire

ASG, Inc., acquired Ockham Development Group, Inc.

synopsis: ASG, Inc. a high-quality functional outsourcing and specialty staffing services group based in Cary, North Carolina - has acquired neighboring Ockham Development Group, Inc., a full-service contract research organization.
buyer: ASG, Inc.
ASG provides high-quality functional outsourcing and specialty staffing services to CROs, pharmaceutical, biotech and medical device companies that require clinical operations, GCP, GLP or GMP auditing, data management, statistical programming, biostatistics and medical writing solutions. "
target: Ockham Development Group, Inc.
Ockham Development Group Inc. is a privately held contract research organization headquartered in Cary, North Carolina.
price ($mm)
rev ($mm)
$12
EBITDA ($mm)
EV / rev
0.0x
EV / EBITDA
closed 4/22/2009 via BusinessWire

PPD, Inc., acquired AbCRO, Inc.

synopsis: PPD, Inc. announced that it has completed the acquisition of AbC.R.O., Inc., a Bulgarian contract research organization. The acquisition strengthens PPD’s ability to provide a broad range of clinical trial management and monitoring, patient recruitment, site identification and regulatory affairs services to its growing client base in the Balkans.
buyer: PPD, Inc.
PPD is a leading global contract research organization (CRO) providing discovery, development and post-approval services as well as compound partnering programs. PPD's clients and partners include pharmaceutical, biotechnology, medical device, academic and government organizations. "
target: AbCRO, Inc.
AbCRO provides a full range of Phase II-IV clinical services, including clinical trial management and monitoring, patient recruitment, site identification and regulatory affairs.
price ($mm)
$36
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
closed 3/20/2009 via PR Newswire

PharmaNet Development Group, Inc. merged with JLL Partners,

synopsis: JLL Partners, a leading private equity investment fund, and PharmaNet Development Group, Inc., a leading provider of clinical development services, announced the successful completion of the tender offer by JLL PharmaNet Holdings, LLC.
buyer: JLL Partners
Founded in 1988, JLL Partners is among the leading private equity investment firms in the country. Since inception, we have managed a series of private equity funds aggregating approximately $4 billion in committed capital. "
target: PharmaNet Development Group, Inc.
PharmaNet Development Group, Inc. is a leader in outsourced clinical development that offers clinical-development solutions including early and late stage consulting services, Phase I clinical studies and bioanalytical analyses, and Phase II, III and IV clinical development programs.
price ($mm)[EV]
$101 [$186]
rev ($mm)
$451
EBITDA ($mm)
$26
EV / rev
0.4x
EV / EBITDA
7.1x
closed 1/27/2009 via BusinessWire

Altarum Institute, acquired KAI Research, Inc.

synopsis: Altarum Institute, a non-profit health systems research and consulting organization, has purchased Rockville, Maryland-based KAI Research, Inc. (KAI). KAI provides innovative, cost-effective and practical support to the pharmaceutical and biotech industry, academic institutions and the National Institutes of Health.
buyer: Altarum Institute
Altarum Institute is a nonprofit health systems research and consulting organization serving government and private-sector clients. "
target: KAI Research, Inc.
KAI Research provides innovative, cost-effective and practical support to the pharmaceutical and biotech industries. KAI currently supports pharmaco-vigilance activities for over 90 marketed drugs and is providing safety surveillance for dozens of ongoing clinical trials.
price ($mm)
$7.55
rev ($mm)
$10
EBITDA ($mm)
EV / rev
0.8x
EV / EBITDA
closed 3/13/2009 via BNC Analysis

Premier Research Group, acquired Pivotal Research Centers, LLC

synopsis: PHC, Inc. d/b/a Pioneer Behavioral Health, a leading provider of inpatient and outpatient behavioral health services, announced Premier Research Arizona, LLC, a unit of Premier Research Group PLC, has signed a purchase agreement to acquire the assets of PHC's Pivotal Research Centers.
buyer: Premier Research Group
Premier Research is a leading solutions-driven CRO committed to therapeutic focus and operational expertise to deliver clinical trial services of the highest quality for biopharmaceutical and medical device companies. "
target parent: Pioneer Behavioral Health
target: Pivotal Research Centers, LLC
Pivotal Research Centers, LLC provides clinical drug testing. It performs all phases of clinical research for Phase I to Phase IV drugs under development through two research sites. Pivotal was founded by Louis C. Kirby in 1993 and is based in Phoenix, Arizona.
price ($mm)
$3.00
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
closed 10/30/2007 via Company Press Release

Chiltern International Inc., acquired Clinical Trial Management Services, Inc.

synopsis: Chiltern, a leading global clinical research organization (CRO), announced the acquisition of Clinical Trial Management Services, Inc. (CTMS) a Bristol, Tennessee based CRO offering high quality services throughout the United States.
buyer: Chiltern International Inc.
Chiltern is a global CRO with experience running and staffing international Phase I to Phase IV clinical trials. Chiltern’s services include: Early Phase, Global Clinical Development, Late Phase, Biometrics, Medical and Regulatory Affairs and Resourcing Solutions. "
target: Clinical Trial Management Services, Inc.
Clinical Trial Management Services, Inc. provides clinical research services such as clinical trial management and monitoring services, such as project management, investigative site management and monitoring services.
price ($mm)
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
closed 12/14/2009 via BusinessWire

NexMed, Inc., acquired Bio-Quant, Inc.

synopsis: NexMed, Inc., a developer of products based on the NexACT® technology, announced the closing of its acquisition of Bio-Quant, Inc., a privately-held leading research organization for in vitro and in vivo contract drug discovery and pre-clinical development services, headquartered in San Diego, CA.
buyer: NexMed, Inc. (NEXM:$0.00)
NexMed is an innovative drug developer that is leveraging its proprietary NexACT® drug delivery technology to produce a host of new medical treatments. NexMed’s drugs address a variety of health conditions, such as nail fungus, sexual disorders and more. "
target: Bio-Quant, Inc.
Founded in 1999, Bio-Quant is the largest specialty CRO based in San Diego and is one of the industry's most experienced CROs for in vitro and in vivo pharmacology services and research models specializing in oncology, inflammation, immunology, and metabolic diseases, including diabetes.
price ($mm)[EV]
$13 [$13]
rev ($mm)
$5
EBITDA ($mm)
EV / rev
2.5x
EV / EBITDA
announced 10/28/2009 via PR Newswire

Alpha Analytical, will acquire Boston Analytical

synopsis: Alpha Analytical is announcing the completion of the acquisition of Boston Analytical, Inc. Established in 1987, Boston Analytical is a registered, cGMP compliant contract testing laboratory providing quality analytical and microbiological testing services to the pharmaceutical, biotech, device, cosmetic and nutritional product industries.
buyer: Alpha Analytical
Alpha Analytical, Inc. provides full-service environmental laboratory solutions for the most demanding industrial and commercial applications in the U.S. and abroad. Alpha Analytical is the largest environmental laboratory in New England and among the top 18 laboratories in the country. "
target: Boston Analytical
Boston Analytical is committed to providing quality Analytical and Microbiological testing services to pharmaceutical companies worldwide in support of their Product Development, Release and Stability Testing objectives.
price ($mm)
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
closed 10/12/2009 via Company Press Release

J O Hambro Capital Management Limited, acquired Celsis International

synopsis: Chicago-based Celsis International, a leading global life sciences company, announces that it has been acquired by UK-based private equity firm J O Hambro and will de-list from the London Stock Exchange (LSE) and operate as a privately held company.
buyer: J O Hambro Capital Management Limited
J O Hambro Capital Management, the London-based boutique investment firm, offers an alternative to the large traditional fund management firms that have dominated the market for many years. "
target: Celsis International
Celsis International plc is a leading international provider of innovative life science products and laboratory services to the pharmaceutical and consumer products industries through our three divisions: Rapid Detection, Analytical Services and In Vitro Technologies.
price ($mm)[EV]
$55 [$52]*
rev ($mm)
$42
EBITDA ($mm)
$12
EV / rev
1.9x
EV / EBITDA
6.3x
closed 7/16/2009 via PR Newswire

Water Street Healthcare Partners, acquired AAIPharma Services

synopsis: Water Street Healthcare Partners, a leading private equity firm focused exclusively on the health care industry, announced that it has acquired the Pharmaceutical Development division from AAIPharma Inc.
buyer: Water Street Healthcare Partners
Water Street Healthcare Partners is a leading private equity firm focused exclusively on health care. With more than $1 billion of capital under management, Water Street is one of the most active investors in the health care industry. "
target parent: AAIPharma Inc.
target: AAIPharma Services
AAIPharma Services serves more than 300 large pharmaceutical and biotechnology companies. Its team of 450 scientists and professionals specialize in services that encompass the entire process of pharmaceutical drug development from discovery through commercialization.
price ($mm)
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
announced 6/1/2009 via Reuters

INC Research, Inc., will purchase Late Stage Research Unit from MDS, Inc.

synopsis: MDS Inc has announced that it planns to narrow its contract research focus by selling its late stage operations and central laboratory divisions to Contract Research Organization INC Research, Inc.
buyer: INC Research, Inc. (SYNH:$4,730.38)
INC Research is a therapeutically focused contract research organization with an unrivaled reputation for conducting Phase I- Phase IV clinical development programs of the highest integrity. "
seller: MDS, Inc. (MDZ:$231.00)
MDS Inc. is a global life sciences company that provides market-leading products and services that are used by its customers for the development of drugs, and the diagnosis and treatment of disease. The Company has more than 5,000 employees in 29 countries and net revenues of more than US$1.2 bil.
price ($mm)
$45
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
closed 4/17/2009 via PR Newswire

ChemRar High-Tech Center, acquired Prudentas, LLC

synopsis: ChemDiv, a global chemistry-driven contract research organization, announced that its ChemRar High Tech Center has acquired Prudentas LLC, one of the leading CRO companies conducting high quality Phase I - Phase IV studies in Eastern Europe.
buyer parent: ChemDiv, Inc.
buyer: ChemRar High-Tech Center
The ChemRar High-Tech Center is a unique pharma and biotechnology complex founded by innovative life science organizations in Russia. ChemRar's component companies are engaged in discovering, developing and commercializing novel drugs for partners in Russia and worldwide. "
target: Prudentas, LLC
Prudentas is a Russian Clinical Contract Research Organization founded by and consisting of highly qualified clinical research professionals with extensive experience of working previously together as a team.
price ($mm)
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA

Like ClinicalAnalytics(R)


read more

TrialStat Corporation

VirTrial

TrialNetworks

Patient Reminders Ltd

Geriatric Practice Management Corp

ManagedCare.com

DatStat, Inc.

ExtendMD, LLC

Prematics, Inc.

Voice-Tech, Inc.

mscripts, LLC

harmo

CareSpeak Communications

Engaged Media LLC

fliiSolutions Inc.

xMatters, inc.

Medago

CUCO Health

CareInSync

PokitDok Inc.

read more

TrialStat Corporation

read more

TrialStat Corporation

read more

Invicro, LLC

Aptuit, Inc.

PAREXEL International Corporation

inVentiv Health, Inc.

Quintiles Transnational Corp.

Excel PharmaStudies Inc.

Encorium Group Inc.

Clinical Trials of the Americas, Inc.

Ockham Development Group, Inc.

AbCRO, Inc.

PharmaNet Development Group, Inc.

KAI Research, Inc.

Pivotal Research Centers, LLC

Clinical Trial Management Services, Inc.

Bio-Quant, Inc.

Boston Analytical

Celsis International

AAIPharma Services

MDS, Inc.

Prudentas, LLC

Geography
Matching Companies
Ticker: VCRA
 
 
 
 
 
 
 
 
Vocera Communications, Inc.
Vocera Communications, Inc.
Vocera Communications, Inc. is the leading provider of voice communications systems designed to restore the human connection to healthcare. Vocera provides integrated communications solutions for both voice and alarm and alert systems.
year
2021
rev ($mm)
$206.41
EBITDA ($mm)
$8.21
EBIT ($mm)
$1.56
Net Income ($mm)
Employees
688
  • drill down
  • watch
Ticker: SYNH
 
 
 
 
 
 
 
 
INC Research, Inc.
INC Research, Inc.
INC Research is a leading global contract research organization ("CRO") providing the full range of Phase I to Phase IV clinical development services for the biopharmaceutical and medical device industries.
year
2021
rev ($mm)
$4,730.38
EBITDA ($mm)
$633.74
EBIT ($mm)
$407.86
Net Income ($mm)
$235.93
Employees
24310
  • drill down
  • watch
Ticker: ICLR
 
 
 
 
 
 
 
 
ICON Plc
ICON Plc
ICON plc is a global provider of outsourced development services to the pharmaceutical, biotechnology and medical device industries. The Company specialises in the strategic development, management and analysis of programs that support clinical development.
year
2015
rev ($mm)
$1,541.91
EBITDA ($mm)
$289.74
EBIT ($mm)
$234.82
Net Income ($mm)
$192.14
Employees
11200
  • drill down
  • watch
Ticker:
 
 
 
 
 
 
 
 
CMIC Co., Ltd.
CMIC is a leading full-service CRO in Japan offering a wide range of services in clinical trials in Asia to both multi-national and Japanese pharma companies.
year
2019
rev ($mm)
$664.65
EBITDA ($mm)
$76.21
EBIT ($mm)
$43.15
Net Income ($mm)
$23.12
Employees
4962
  • drill down
  • watch
Ticker: PIELF
 
 
 
 
 
 
 
 
Pierrel SpA
Pierrel SpA
Pierrel S.p.A. is a pharmaceutical company specializing in contract research, development and the manufacture of medicines. The Pierrel Group boasts over 50 years of experience in the pharmaceutical sector, and is one of the main Italian manufacturers of local anaesthetics for dental use.
year
2008
rev ($mm)
$64.38
EBITDA ($mm)
($4.23)
EBIT ($mm)
($8.92)
Net Income ($mm)
Employees
504
  • drill down
  • watch
Ticker: ENCO
 
 
 
 
 
 
 
 
Encorium Group Inc.
Encorium is a full-service Contract Research Organization providing comprehensive solutions for pharmaceutical, biotechnology, and medical device companies. At Encorium we recognize the challenges that often arise during drug development.
year
2008
rev ($mm)
$35.91
EBITDA ($mm)
($5.19)
EBIT ($mm)
($6.89)
Net Income ($mm)
Employees
226
  • drill down
  • watch
Ticker: ENXTPA:ERF
 
 
 
 
 
 
 
 
Eurofins Group
Eurofins Group
Based in Luxembourg, Eurofins is a leading international group of laboratories providing a unique range of analytical testing services to the pharmaceutical, food, environmental and consumer products industries and to governments.
year
2019
rev ($mm)
$5,244.00
EBITDA ($mm)
$922.65
EBIT ($mm)
$524.54
Net Income ($mm)
$224.34
Employees
47427
  • drill down
  • watch
Ticker: CRL
 
 
 
 
 
 
 
 
Charles River Laboratories International Inc.
Charles River Laboratories International Inc.
Charles River has been helping our global partners accelerate drug discovery and development by providing them with tailored research models and preclinical, clinical, support services.
year
2009
rev ($mm)
$1,202.55
EBITDA ($mm)
$282.48
EBIT ($mm)
$188.93
Net Income ($mm)
$114.44
Employees
8000
  • drill down
  • watch
Ticker: NEO
 
 
 
 
 
 
 
 
NeoGenomics Laboratories
NeoGenomics Laboratories
NeoGenomics is a leading cancer diagnostic reference laboratory. NeoGenomics offers testing services for oncologists, pathologists, and pharmaceutical centers. Their areas of expertise include cancer cytogenetics, hematologic and solid tumor FISH testing, molecular oncology tests, and more.
year
2020
rev ($mm)
$444.45
EBITDA ($mm)
$23.80
EBIT ($mm)
($11.92)
Net Income ($mm)
$4.17
Employees
1700
  • drill down
  • watch
Ticker: LH
 
 
 
 
 
 
 
 
LabCorp
LabCorp provides leading-edge medical laboratory tests and services through a national network of primary clinical laboratories and specialty testing laboratories. LabCorp processes tests on approximately 470,000 specimens each day, applying advances in medicine and science to laboratory testing.
year
2021
rev ($mm)
$16,388.10
EBITDA ($mm)
$4,886.00
EBIT ($mm)
$4,358.30
Net Income ($mm)
$2,878.70
Employees
68780
  • drill down
  • watch